- Home
- SNGX
SNGX
Soligenix Inc.
as of 03-06-2026 3:58pm EST
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 11.8M | IPO Year: | 2006 |
| Target Price: | $6.00 | AVG Volume (30 days): | 121.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.30 | EPS Growth: | -530.38 |
| 52 Week Low/High: | $1.02 - $6.23 | Next Earning Date: | N/A |
| Revenue: | $119,371 | Revenue Growth: | -85.78% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.50 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered SNGX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2016 Q2 Q2 2016 Earnings
8-K Aug 12, 2016
Q2 2016 Earnings
8-KAug 12, 2016
8-K 1 f8k081116_soligenix.htm
CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 11, 2016
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
DELAWARE
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 11, 2016, Soligenix, Inc. (the “Company”) issued a press release announcing its results of operations for the second quarter ended June 30, 2016. A copy of the press release is attached as Exhibit 99.1 to this report.
The information in this report, including the exhibit hereto, is being “furnished” in accordance with General Instruction B.2 of Form 8-K. As such, this information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filings with the Securities and Exchange Commission unless it is explicitly so incorporated in such filings.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Title
99.1
Press release issued by the Company on August 11, 2016.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
August 11, 2016 By: /s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
2013 Q2 Q2 2013 Earnings
8-K Aug 21, 2013
Q2 2013 Earnings
8-KAug 21, 2013
8-K 1 f8k081213_soligenix.htm
CURRENT REPORT
f8k081213_soligenix.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 12, 2013
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
DELAWARE
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 12, 2013, Soligenix, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2013. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Title
99.1
Press release issued by the Company on August 12, 2013.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
By:
/s/ Christopher J. Schaber
August 21, 2013
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
EXHIBIT INDEX
Exhibit No.
Title
99.1
Press release issued by the Company on August 12, 2013.
2013 Q1 Q1 2013 Earnings
8-K May 8, 2013
Q1 2013 Earnings
8-KMay 8, 2013
8-K 1 f8k050313_soligenix.htm
CURRENT REPORT
f8k050313_soligenix.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 3, 2012
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
DELAWARE
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On May 3, 2013, Soligenix, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended March 31, 2013. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Title
99.1
Press release issued by the Company on May 3, 2013.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
By: /s/ Christopher J. Schaber
May 8, 2013
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
EXHIBIT INDEX
Exhibit No.
Title
99.1
Press release issued by the Company on May 3, 2013.
Compare SNGX vs Leading Stocks
See how SNGX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SNGX Soligenix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.